- Job Market Politics to Keep Interest Rates Low
- AIG, Symbol of Crisis, Watches Its Stock Zoom Back
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Bill Gates Praises Apple's Jobs for 'Saving the Company'
- Cities With the Most Home Price Reductions
- Cramer: The Real Reason Stocks Fell Thursday
- Is Euphoric Market Ignoring Warning Signs?
- Video Game Sales Plunge, but Have They Hit Bottom?
- Despite Rhetoric, Obama Has Few Options to Boost Jobs
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Gold Is a Bad Inflation Hedge—Like Oil: Stock Picker
- Intel's Andy Bryant Offers An Explanation
- US 'Actively Working' on Weaker Dollar: Fund Manager
- Options Boil on Biotech Buyout Rumors
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Activision Blizzard's "Modern Warfare 2" Sales Break Records
- 5-Star Manager's 5 Stocks for Changing Markets
- What's The Forecast from Retailers? Proceed With Caution
MOST SHARED
- Warren Buffett and Bill Gates Share Their 'Optimism' With Eager Columbia Business Students
- Meet The Leaders of the New Retail Revolution
- Cities With the Most Home Price Reductions
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Housing Recovery 'Still In Uncharted Territory': HUD Secretary
- Is Euphoric Market Ignoring Warning Signs?
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Despite Rhetoric, Obama Has Limited Options To Boost Jobs
- Disney CFO and Parks Chief to Swap Roles
Text Size 
A trial of Celgene's [CELG
Loading...
()
] cancer drug Revlimid was temporarily suspended as of April 4, according to the Southwest Oncology Group, or SWOG, which was running the late-stage trial.
The statement, made on the group's Web site, did not give details.
However, Matthew Osborne, an analyst at Lazard Capital Markets, said he believes the suspension is designed to alter the protocol to allow patients to switch to a different treatment regimen, which was recently shown to improve survival.
Brian Gill, a spokesman for Celgene, confirmed that the trial has been temporarily closed but said the company could shed no light on the reason for the suspension.
"Matt Osborne's assumptions are very interesting and could well have validity but we don't have any definitive information," he said.
The SWOG study is testing Revlimid plus standard dose dexamethasone, a steroid, versus dexamethasone alone as a first-line treatment for multiple myeloma.
The news comes on the heels of a recent finding by the Eastern Cooperative Oncology Group, or ECOG, that patients who took Revlimid plus low-dose dexamethasone had a survival advantage over patients who took Revlimid plus standard dose dexamethasone.
It is not clear whether SWOG plans to stop the trial completely, but Osborne said that with a survival advantage for Revlimid plus low-dose dexamethasone it could be considered unethical to continue patients on standard dose dexamethasone alone.
"What this does is build on the evidence that Revlimid plus low-dose dexamethasone will become the standard of care in frontline multiple myeloma," Osborne said.
Currently, Revlimid is approved by the U.S. Food and Drug Administration in combination with standard-dose dexamethasone for patients with multiple myeloma who have received at least one prior therapy.
Osborne said, however, that as data from the Revlimid plus dexamethasone trials is further disseminated, physicians are likely to increase their use of Revlimid plus low-dose dexamethasone as their first choice therapy, even though it has not formally been approved for such use.
Physicians are allowed to prescribe drugs "off label" but companies are not allowed to market them for unapproved uses.
Revlimid is a successor to Celgene's drug Thalomid, currently the leading treatment for multiple myeloma.
Print
Email
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- They may have wrecked their companies or saved our economy. Tell us what you think.
- Big pharma embraces social media, but how much should a tightly regulated sector say on Facebook or Twitter?
- A European dating site finds lovelorn singles from one country to be consistently uglier. Which is it?
- Contributor David Pogue looks at two of the latest efforts to perfect the digital pocket camera.
- PepsiCo is ramping up its onsite health facilities for workers.
Data is a real-time snapshot *Data is delayed at least 15 minutes